It depends on how that is structured and what the approach is. Right now a portion of that $29 billion is already covered by public drug programs that are in place in the jurisdictions and with the federal government, but there is that private sector piece. It really depends what type of model and approach was used for a pharmacare program.
On April 13th, 2016. See this statement in context.